Jonas Salk Announces Polio Vaccine Success

Context

Poliomyelitis outbreaks struck the United States repeatedly in the first half of the twentieth century, with major epidemics beginning in the 1890s and recurring each summer. The virus spread through contaminated water and food, striking mainly children and young adults and often leaving survivors with permanent paralysis of the limbs or respiratory muscles. Treatment remained limited to isolation, physical therapy, and the iron lung respirator for those whose breathing was affected. Franklin D. Roosevelt’s 1921 infection at age thirty-nine drew national attention to the disease and later helped channel private philanthropy into research through the National Foundation for Infantile Paralysis, later known as the March of Dimes.

What Happened

Jonas Salk, who had joined the University of Pittsburgh School of Medicine in 1947 to direct its virus research laboratory, received foundation support in 1948 to pursue a polio vaccine. Building on earlier work that showed multiple virus strains could be inactivated, Salk developed a killed-virus preparation and conducted small-scale safety tests on recovered polio patients, laboratory staff, and eventually his own family. By early 1953 he had sufficient data to go public. On the evening of March 26 he appeared on the CBS radio network and stated that the vaccine had produced antibodies without causing disease in the initial subjects. Two days later he published the findings in the Journal of the American Medical Association.

Aftermath

The announcement triggered immediate expansion of testing. In 1954 a controlled field trial enrolled roughly 1.8 million schoolchildren across the United States, Canada, and Finland, with results evaluated by an independent center at the University of Michigan. On April 12, 1955, the vaccine was declared safe and effective, prompting rapid licensing and a nationwide immunization campaign. A manufacturing error at Cutter Laboratories later that year caused a cluster of cases, temporarily halting production and prompting stricter oversight, but overall incidence fell sharply once distribution resumed.

Legacy

Widespread use of the Salk vaccine, followed by Albert Sabin’s oral live-virus version licensed in 1962, reduced reported U.S. polio cases from more than 58,000 in 1952 to fewer than 1,000 by the early 1960s. The episode strengthened public confidence in systematic vaccine development and large-scale clinical trials. Salk’s decision not to patent the vaccine ensured low-cost global distribution and set a precedent for philanthropic approaches to infectious-disease control that continue in contemporary eradication campaigns.